CLYM19132 / A051701 / Patrick ReaganResearch Question:
This study tests whether it is possible to decrease the chance of high-grade B-cell
lymphomas returning or getting worse by adding a new drug, venetoclax to the usual
combination of drugs used for treatment.
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II/III trial tests whether it is possible to decrease the chance of high-grade
B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the
usual combination of drugs used for treatment. Venetoclax may stop the growth of cancer
cells by blocking a protein called Bcl-2. Drugs used in usual chemotherapy, such as
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide,
work in different ways to stop the growth of cancer cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. Giving venetoclax
together with usual chemotherapy may work better than usual chemotherapy alone in
treating patients with high-grade B-cell lymphomas, and may increase the chance of
cancer going into remission and not returning.
Study Reference #: CLYM19132
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search